Phronesis Artificial Intelligence
Phronesis AI develops advanced pharmaceutical software for autonomous drug discovery and disease targeting.
Founded
2020Phronesis AI develops advanced pharmaceutical software for autonomous drug discovery and disease targeting.
Phronesis Artificial Intelligence, founded with the mission to revolutionize drug discovery, focuses on developing advanced pharmaceutical software. Its core platform, LIME, leverages cutting-edge AI technology and extensive molecular data to autonomously design new drug candidates and target specific diseases. The company's vision is to streamline and accelerate the drug discovery process, making it more efficient and effective for pharmaceutical companies and researchers.
Notable figures affiliated with Phronesis AI include leading experts in artificial intelligence and pharmaceutical sciences. The company has garnered attention from prominent investors in the biotech and AI sectors. Key achievements include significant advancements in AI-driven drug design and successful collaborations with major pharmaceutical firms. Phronesis AI's impact lies in its potential to transform the landscape of drug discovery, offering faster and more precise solutions for developing new medicines.
Companies similar to Phronesis Artificial Intelligence include Iambic Therapeutics, TandemAI, Model Medicines and Cognaisent.
Phronesis Artificial Intelligence was founded in 2020.
Phronesis Artificial Intelligence's headquarters is located in Daphne, AL, US.
Phronesis Artificial Intelligence's most recent funding round was for $300k (USD) in September 2021.
As of Sep 8, 2021, Phronesis Artificial Intelligence has disclosed funding of $300k (USD). Undisclosed round amounts are excluded.
Phronesis Artificial Intelligence has 7 employees as of Feb 5, 2024.
Cognaisent
cognaisent.com
